Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gw Pharmaceuticals plc
Headquarters: Cambridge, United Kingdom
Website: N/A
Year Founded: 1998
Status: Acquired
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Oct 19, 2022
Deals
With biliary readout looming, Jazz-Zymeworks deal could grow much larger
Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout
BioCentury | Jul 16, 2022
Management Tracks
Aurinia hires EVP of R&D, commercial head and VP of IR
Plus Enveda names Gilead’s Sekar as CBO and Covis hires a Poulin as SVP, general manager
BioCentury | Jun 29, 2022
Product Development
June 28 Quick Takes: Roivant, Pfizer create start-up to house TYK2/JAK1 program
Plus Jazz’s Sativex misses and updates from Sanofi, Spero, SonALAsense and more
BioCentury | Apr 8, 2022
Deals
Werewolf deal gives Jazz first immuno-oncology candidate
Jazz pays $15M up front to in-license rights to Werewolf’s conditionally activated oncology therapeutic
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Jan 19, 2022
Deals
UCB pads epilepsy portfolio with $1.9B Zogenix takeout
With UCB patent cliff looming, Zogenix takeout comes ahead of possible Fintepla label expansion
BioCentury | Sep 30, 2021
Deals
PAH candidate central to Merck’s $11.5B Acceleron takeout
Pharma views Acceleron’s sotatercept as growth driver following Keytruda patent expiration
BioCentury | Aug 19, 2021
Regulation
Aug. 18 Quick Takes: Jardiance’s label gains heart failure indication
RA leads $50M series B for Jnana, plus a deal for Verily, no deal for CureVac and Marinus data
BioCentury | Aug 3, 2021
Deals
A $3.2B takeout of partner Translate Bio tees Sanofi up to build out mRNA franchise
Year’s second-largest biotech buyout caps nearly 200% stock run sparked by COVID program
Items per page:
1 - 10 of 234